[Recent medication to renal osteodystrophy]

P control according to phosphorus (P) adsorbent by the medication to renalosteodystrophy (ROD) and the medical treatment by active vitamin D are main. Although the present calcium carbonate is used as P adsorbent, sufficient quantity to control P for hypercalcemia may be unable to be prescribed for the patient. The near future use of sevelamer hydrochloride under development which does not cause hypercalcemia will be attained at such a case. Although alphacalcidol and calcitriol are used for some time, the present clinical use of the vitamin derivatives which made calcitriol basic structure and made the action powerful, such as maxacalcitol and falecalcitriol, is developed and carried out. Thus, although the choice of vitamin D medical treatment increased by clinical use of much active vitamin D or its derivative having been attained and the adaptation range also spread, there is no view which now unified how such a medicine would be used properly. The validity to ROD, such as calcitonin, vitamin K, and bisphosphonates, is examined in addition to P adsorbent, or vitamin D and its derivative, and calcimimetics is developed as a new medicine.